EIF2AK2 and neurodegenerative disease: Currently, selective and bioavailable inhibitors of PERK (Axten et al., 2012; Moreno et al., 2013) and PKR (Couturier et al., 2010, 2012) are developed for neurodegenerative disease therapy, although their potential adverse effects (e.g., hyperglycemia with PERK inhibitors) need to be carefully addressed.